Literature DB >> 46260

IgA and IgA diphtheria antitoxin responses from human tonsil lymphocytes.

T A Platts-Mills, K Ishizaka.   

Abstract

Human tonsil lymphocytes were stimulated with diphtheria toxoid and then cultured in a Marbrook culture system so that antibodies could be measured in the culture supernatant. Specific antibodies were measured with excess radiolabeled antigen and antisera specific for each immunoglobulin class. Good IgG and IgA diphtheria antitoxin responses have been obtained and responding culture supernatants were shown to neutralize toxin. The relationship between antitoxin response in vitro and immunization of donors with toxoid was investigated. It was found that at least two immunizations after the age of 6 months were necessary to prime the tonsils for an in vitro antibody response. The IgG and IgA in culture supernatants were demonstrated by immunodiffusion and were measured by radioimmunoassay. By sucrose density gradient ultracentrifugation, it was shown that 40% of the IgA produced in the cultures was greater than 7S. Evidence was obtained that neither the IgA nor the specific IgA antitoxin bears secretory piece. It appears that human lymphocytes from tonsils produce polymer IgA in vitro without secretory piece.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 46260

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  The effects of purified mitogenic proteins (Pa-1 and Pa-2) from pokeweed on human T and B lymphocytes in vitro.

Authors:  G Janossy; E Gomez De La Concha; M J Waxdal; T Platts-Mills
Journal:  Clin Exp Immunol       Date:  1976-10       Impact factor: 4.330

2.  Immunological and purine enzyme studies on hyperuricaemic and normouricaemic patients with Down's syndrome.

Authors:  R W Watts; Y S Perera; J Allsop; C Newton; T A Platts-Mills; A D Webster
Journal:  Clin Exp Immunol       Date:  1979-06       Impact factor: 4.330

3.  Functional studies on T cells in adult human bone marrow.

Authors:  G C De Gast; T A Platts-Mills
Journal:  Clin Exp Immunol       Date:  1979-10       Impact factor: 4.330

4.  Comparison of IgE expression at the mRNA and protein levels in vitro.

Authors:  K J Turner; J Creany; R J Coelen; K J Cameron; B J Holt; M W Beilharz
Journal:  Immunology       Date:  1991-12       Impact factor: 7.397

5.  Susceptibility of human lymphocyte populations to infection by herpes simplex virus.

Authors:  B K Pelton; R C Imrie; A M Denman
Journal:  Immunology       Date:  1977-05       Impact factor: 7.397

6.  Quantitative measurements of T- and B-cell function in "variable" primary hypogammaglobulinaemia: evidence for a consistent B-cell defect.

Authors:  E G de la Concha; G Oldham; A D Webster; G L Asherson; T A Platts-Mills
Journal:  Clin Exp Immunol       Date:  1977-02       Impact factor: 4.330

7.  Human nasopharyngeal-associated lymphoreticular tissues. Functional analysis of subepithelial and intraepithelial B and T cells from adenoids and tonsils.

Authors:  P N Boyaka; P F Wright; M Marinaro; H Kiyono; J E Johnson; R A Gonzales; M R Ikizler; J A Werkhaven; R J Jackson; K Fujihashi; S Di Fabio; H F Staats; J R McGhee
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

8.  IgA and IgG anti-ragweed antibodies in nasal secretions. Quantitative measurements of antibodies and correlation with inhibition of histamine release.

Authors:  T A Platts-Mills; R K von Maur; K Ishizaka; P S Norman; L M Lichtenstein
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

9.  Glucocorticosteroid enhancement of immunoglobulin synthesis by pokeweed mitogen-stimulated human lymphocytes. III. Common variable immunodeficiency.

Authors:  D A Cooper; P Hansen; M Duckett; J B Ziegler; R Penny
Journal:  Clin Exp Immunol       Date:  1981-08       Impact factor: 4.330

10.  Cancer antigens are expressed in a carcinogen-transformed Bloom syndrome B-lymphoblastoid cell line.

Authors:  Y Shiraishi; H Soma
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.